Literature DB >> 33572084

Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK.

Sidrah Shah1, Mikolaj Kutka1, Kathryn Lees2, Charlotte Abson2, Maher Hadaki2, Deirdre Cooke1, Cherie Neill1, Matin Sheriff3, Afroditi Karathanasi1, Stergios Boussios1,4,5.   

Abstract

INTRODUCTION: Malignant spinal cord compression (MSCC) is one of the most devastating complications of cancer. This event requires rapid decision-making on the part of several specialists, given the risk of permanent spinal cord injury or death. The goals of treatment in spinal metastases are pain control and improvement of neurological function. There can be challenges in delivering prompt diagnosis and treatment in a secondary care setting. We have reflected on the experience of managing MSCC in a district general setting. AIM: Our retrospective audit identified 53 patients with suspected MSCC who entered the relevant pathway from April 2017 to March 2018 at Medway, United Kingdom (UK). Our audit standards were set out by Medway Maritime Hospital and Maidstone and Tunbridge Wells NHS Trust MSCC working group members, using a combination of published evidence and best practice.
RESULTS: The patients with suspected MSCC were 53 and 29 of them (54.7%) had confirmed MSCC. The most common malignancies within the confirmed MSCC were lung (11 patients, 37.9%), breast (5 patients 17.2%), and renal (3 patients, 10.3%), followed by prostate, myeloma and carcinoma of unknown primary (2 patients (6.9%) each), as well as pancreatic, colorectal, lymphoma and, bladder (1 patient (3.4%) each). A magnetic resonance imaging (MRI) scan was performed in 48 patients (90.5%); the majority (31 patients, 64.6%) underwent the MRI within the first 24 h, whereas 3 patients had the investigation between 24 and 72 h from the admission. Among the 29 patients with confirmed MSCC, 6 (20.6%) were treated with surgical decompression, while 20 (69%) received radiotherapy (RT) and 3 (10.3%) best supportive care, respectively. Median time to surgery was 5 days (ranged between 2 and 8 days), whereas for RT 44.4 h (ranged between 24 and 72 h). Finally, all 3 patients that decided on symptom control were referred to a palliative care team within the first 24 h following the MRI scan.
CONCLUSIONS: MSCC is frequently presented outside tertiary care. This may cause subsequent delays in investigation, diagnosis, and treatment, which can be improved by following a fast track referral pathway.

Entities:  

Keywords:  corticosteroids; decompressive surgery; metastatic spinal cord compression; palliative radiotherapy; pathway

Year:  2021        PMID: 33572084      PMCID: PMC7914482          DOI: 10.3390/jpm11020110

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  21 in total

1.  Reliability analysis of the epidural spinal cord compression scale.

Authors:  Mark H Bilsky; Ilya Laufer; Daryl R Fourney; Michael Groff; Meic H Schmidt; Peter Paul Varga; Frank D Vrionis; Yoshiya Yamada; Peter C Gerszten; Timothy R Kuklo
Journal:  J Neurosurg Spine       Date:  2010-09

2.  Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.

Authors:  Roy A Patchell; Phillip A Tibbs; William F Regine; Richard Payne; Stephen Saris; Richard J Kryscio; Mohammed Mohiuddin; Byron Young
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

3.  A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease.

Authors:  Paul Klimo; Clinton J Thompson; John R W Kestle; Meic H Schmidt
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

Review 4.  Malignant spinal cord compression.

Authors:  A Graham Macdonald; Daniel Lynch; Ian Garbett; Nauzan Nazeer
Journal:  J R Coll Physicians Edinb       Date:  2019-06

5.  Treatment of spinal cord compression: are we overusing radiotherapy alone compared to surgery and radiotherapy?

Authors:  Jonathon Hutton; John Leung
Journal:  Asia Pac J Clin Oncol       Date:  2012-10-09       Impact factor: 2.601

6.  An audit of current practice and management of metastatic spinal cord compression at a regional cancer centre.

Authors:  J Sui; J S Fleming; M Kehoe
Journal:  Ir Med J       Date:  2011-04

Review 7.  Metastatic spinal cord compression: diagnosis and management.

Authors:  Rasha Al-Qurainy; Emily Collis
Journal:  BMJ       Date:  2016-05-19

8.  Effect of timing of surgery on neurological outcome and survival in metastatic spinal cord compression.

Authors:  N A Quraishi; T S Rajagopal; S R Manoharan; S Elsayed; K L Edwards; B M Boszczyk
Journal:  Eur Spine J       Date:  2012-12-30       Impact factor: 3.134

9.  Factors related to the outcome of inpatient rehabilitation in patients with neoplastic epidural spinal cord compression.

Authors:  H G Hacking; H H Van As; G J Lankhorst
Journal:  Paraplegia       Date:  1993-06

10.  Don't wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression.

Authors:  P Levack; J Graham; D Collie; R Grant; J Kidd; I Kunkler; A Gibson; D Hurman; N McMillan; R Rampling; L Slider; P Statham; D Summers
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-12       Impact factor: 4.126

View more
  3 in total

1.  Separation Surgery in the Treatment of Spinal Metastasis.

Authors:  Rui-Feng Li; Rui-Qi Qiao; Ming-You Xu; Rong-Xing Ma; Yong-Cheng Hu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 2.  Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review.

Authors:  Ruben Van den Brande; Erwin Mj Cornips; Marc Peeters; Piet Ost; Charlotte Billiet; Erik Van de Kelft
Journal:  J Bone Oncol       Date:  2022-07-09       Impact factor: 4.491

Review 3.  State-of-the-Art Imaging Techniques in Metastatic Spinal Cord Compression.

Authors:  Tricia Kuah; Balamurugan A Vellayappan; Andrew Makmur; Shalini Nair; Junda Song; Jiong Hao Tan; Naresh Kumar; Swee Tian Quek; James Thomas Patrick Decourcy Hallinan
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.